{"corpus_id":28529639,"paper_sha":"894f2b5f3d8241b2747ec6c2461b903e0e8ee5ed","doi":"10.5603/EP.a2016.0018","arxiv_id":null,"pmid":26884288,"pmcid":null,"mag_id":2411038331,"dblp_id":null,"acl_id":null,"title":"Complete recovery of visual acuity as the main goal of treatment in patients with dysthyroid optic neuropathy.","year":2016,"publication_date":null,"venue":"Endokrynologia Polska","journal":{"name":"Endokrynologia Polska","pages":"\n          166-73\n        ","volume":"67 2"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article"],"s2_fields_of_study":["Medicine"],"reference_count":24,"citation_count":31,"influential_citation_count":1,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Adult","mj":false,"ui":"D000328"},{"d":"Aged","mj":false,"ui":"D000368"},{"d":"Color Vision Defects","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"surgery","mj":false,"ui":"Q000601"}],"ui":"D003117"},{"d":"Combined Modality Therapy","mj":false,"ui":"D003131"},{"d":"Decompression, Surgical","mj":true,"ui":"D019299"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Graves Ophthalmopathy","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"surgery","mj":false,"ui":"Q000601"}],"ui":"D049970"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Male","mj":false,"ui":"D008297"},{"d":"Methylprednisolone","mj":false,"qs":[{"q":"therapeutic use","mj":true,"ui":"Q000627"}],"ui":"D008775"},{"d":"Middle Aged","mj":false,"ui":"D008875"},{"d":"Optic Nerve Diseases","mj":false,"qs":[{"q":"drug therapy","mj":true,"ui":"Q000188"},{"q":"surgery","mj":false,"ui":"Q000601"}],"ui":"D009901"},{"d":"Retrospective Studies","mj":false,"ui":"D012189"},{"d":"Treatment Outcome","mj":false,"ui":"D016896"},{"d":"Visual Acuity","mj":true,"ui":"D014792"}],"chemicals":[{"n":"Methylprednisolone","ui":"D008775","reg":"X4W7ZR7023"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"https://journals.viamedica.pl/endokrynologia_polska/article/download/EP.a2016.0018/31613","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/894f2b5f3d8241b2747ec6c2461b903e0e8ee5ed","s2_open_access_license":"CCBYNCND","s2_open_access_status":"GOLD","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"INTRODUCTION\nTo evaluate the effectiveness of methylprednisolone (MP) and surgical treatment in achieving complete reversal of dysthyroid optic neuropathy (DON) and predictive factors of this therapy.\n\n\nMATERIAL AND METHODS\nThe group consisted of 10 patients (18 eyes) with DON. The diagnosis of DON was based on at least two criteria from the following: (i) deterioration of visual acuity (VA< 1.0), (ii) loss of colour vision, (iii) optic disc swelling, and/or (iv) signs of DON in magnetic resonance imaging (presence of apical crowding and/or optic nerve stretching). A complete recovery of DON was defined as the normalisation of VA (VA = 1.0), normal colour vision, and reversal of optic disc swelling. A significant improvement was defined as improvement of VA of at least 0.2. The consecutive steps of treatment of DON consisted of: (i) first-line treatment - intravenous MP pulse therapy (3 × 1 g); (ii) second-line treatment - endoscopic intranasal orbital decompression of medial wall; (iii) additional treatment - additional MP therapy and/or surgical decompression.\n\n\nRESULTS\nA significant improvement in VA could be achieved in the majority of patients; a complete recovery was noted in 22.2%, 33.3%, and 66.7% of eyes after first-line, second-line, and additional treatment, respectively. Positive predictive factors were: younger age (p = 0.049), shorter duration of DON (p = 0.035), and a higher Graves' orbitopathy clinical activity score (p = 0.035).\n\n\nCONCLUSIONS\nBy using combination therapy (intravenous MP pulse therapy and surgical decompression), a complete recovery can be achieved in the majority of patients with DON.","claims":[{"public_id":"cl_ed3d77d706abfdd1420613788e23cbba","status":"active","text":"Complete recovery of dysthyroid optic neuropathy was achieved in a majority of patients using combination therapy with intravenous methylprednisolone pulse therapy and surgical decompression.","confidence":0.96,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_ed3d77d706abfdd1420613788e23cbba"},{"public_id":"cl_89255bcc216d3ea320de111815ebe46c","status":"active","text":"Complete recovery rates increased from 22.2% after first-line treatment to 33.3% after second-line treatment and 66.7% after additional treatment.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_89255bcc216d3ea320de111815ebe46c"},{"public_id":"cl_e80a37d63ccb6520684117aa25f831b5","status":"active","text":"Younger age, shorter duration of dysthyroid optic neuropathy, and a higher Graves' orbitopathy clinical activity score were positive predictive factors for treatment response.","confidence":0.94,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_e80a37d63ccb6520684117aa25f831b5"}],"concepts":[{"public_id":"co_0c208346c8f998bcf69d1ad360a2a30c","status":"active","name":"first-line treatment","description":"The initial treatment step consisting of intravenous methylprednisolone pulse therapy.","types":["treatment stage"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0c208346c8f998bcf69d1ad360a2a30c"},{"public_id":"co_0f71eff9cc2454e621a1f94729b11e80","status":"active","name":"complete recovery","description":"Normalization of visual acuity, normal color vision, and reversal of optic disc swelling as defined in the study.","types":["outcome"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0f71eff9cc2454e621a1f94729b11e80"},{"public_id":"co_16bfeb998987307fc0f79ee7d4eee6ed","status":"active","name":"predictive factors","description":"Patient or disease characteristics associated with treatment outcome in the reported cohort.","types":["statistical factor"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_16bfeb998987307fc0f79ee7d4eee6ed"},{"public_id":"co_30542ca6cac08d2bb07f33a01960c1cf","status":"active","name":"magnetic resonance imaging","description":"Imaging modality used here to identify apical crowding and optic nerve stretching.","types":["imaging modality"],"aliases":["MRI"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_30542ca6cac08d2bb07f33a01960c1cf"},{"public_id":"co_3f2e09a043b3d3cd3f542bee77efa64d","status":"active","name":"Graves' orbitopathy clinical activity score","description":"A clinical score used to assess activity of Graves' orbitopathy.","types":["measurement"],"aliases":["clinical activity score","CAS"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_3f2e09a043b3d3cd3f542bee77efa64d"},{"public_id":"co_4c0e7a29a90c9f2342385850fd543b89","status":"active","name":"visual acuity","description":"A measure of visual sharpness used here to assess recovery in eyes with dysthyroid optic neuropathy.","types":["outcome measure"],"aliases":["VA"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_4c0e7a29a90c9f2342385850fd543b89"},{"public_id":"co_5cd78df9e4eeeb5c790182c0683774d2","status":"active","name":"colour vision","description":"The ability to distinguish colors, used here as part of the recovery definition.","types":["outcome measure"],"aliases":["color vision"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_5cd78df9e4eeeb5c790182c0683774d2"},{"public_id":"co_81a331294456b1d716a0411c9272c4b0","status":"active","name":"optic disc swelling","description":"Swelling of the optic nerve head, used here as part of the diagnostic and recovery criteria.","types":["sign"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_81a331294456b1d716a0411c9272c4b0"},{"public_id":"co_91fa27b284d87b5da8539c977d1d4a3b","status":"active","name":"dysthyroid optic neuropathy","description":"Optic nerve dysfunction associated with thyroid eye disease, assessed here by visual and imaging criteria.","types":["condition"],"aliases":["DON"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_91fa27b284d87b5da8539c977d1d4a3b"},{"public_id":"co_9e67f94428a1f802e7e7015519caaecf","status":"active","name":"additional treatment","description":"Extra treatment with further methylprednisolone and/or surgical decompression after the initial steps.","types":["treatment stage"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_9e67f94428a1f802e7e7015519caaecf"},{"public_id":"co_a6dc0e88449874ba44dc8f3d82a5b82b","status":"active","name":"surgical decompression","description":"Operative orbital decompression used to relieve optic nerve compression.","types":["treatment"],"aliases":["endoscopic intranasal orbital decompression","orbital decompression"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_a6dc0e88449874ba44dc8f3d82a5b82b"},{"public_id":"co_aad15faaf74de2e66d56d59ad7bdd4bd","status":"active","name":"second-line treatment","description":"The next treatment step consisting of endoscopic intranasal orbital decompression of the medial wall.","types":["treatment stage"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_aad15faaf74de2e66d56d59ad7bdd4bd"},{"public_id":"co_e8236166c61305a9ee565773968e5793","status":"active","name":"intravenous methylprednisolone pulse therapy","description":"High-dose intravenous methylprednisolone administered in pulses as the initial treatment step.","types":["treatment"],"aliases":["MP pulse therapy","methylprednisolone"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_e8236166c61305a9ee565773968e5793"}],"external_ids":{"DOI":"10.5603/EP.a2016.0018","ArXiv":null,"PubMed":26884288,"PubMedCentral":null,"MAG":2411038331,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"https://journals.viamedica.pl/endokrynologia_polska/article/download/EP.a2016.0018/31613","landing_url":"https://www.semanticscholar.org/paper/894f2b5f3d8241b2747ec6c2461b903e0e8ee5ed","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBYNCND","status":"GOLD","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":631067,"paper_uid":"77a6f27c-2de0-4f90-8b18-b1e7acd4629b","canonical_identity":{"paper_id":631067,"paper_uid":"77a6f27c-2de0-4f90-8b18-b1e7acd4629b","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/28529639"}